- Home
- Automated
- List of product information
- MALTOFER DROPS 50 MG/ML [SIN05699P]
MALTOFER DROPS 50 MG/ML [SIN05699P]
Active ingredients: MALTOFER DROPS 50 MG/ML
On this page
Product Info
MALTOFER DROPS 50 MG/ML
[SIN05699P]
Product information
Active Ingredient and Strength | IRON HYDROXIDE POLYMALTOSE EQV IRON - 50 MG/ML |
Dosage Form | SOLUTION |
Manufacturer and Country | VIFOR SA - SWITZERLAND |
Registration Number | SIN05699P |
Licence Holder | VIFOR PHARMA ASIA PACIFIC PTE. LTD. |
Forensic Classification | GENERAL SALE LIST |
Anatomical Therapeutic Chemical (ATC) code | B03AB05 |
Therapeutic indications
Treatment of iron deficiency without anaemia and iron deficiency anaemia.
Prophylactic therapy of iron deficiency to cover the recommended daily dietary allowances (RDA) during pregnancy and lactation, for children, adolescents and adults (e.g. vegetarians and elderly).
Posology
Dosage and duration of therapy are dependent upon the extent of iron deficiency.
Iron deficiency anaemia: the therapy takes about 3–5 months until a normalisation of the haemoglobin value is achieved. Afterwards the therapy should be continued for several weeks, or for pregnant women, at least until the end of the pregnancy with a dosage such as described for iron deficiency without anaemia in order to replenish the iron stores.
Iron deficiency without anaemia: the therapy takes about 1–2 months.


Method of administration
The daily dosage can be divided into separate doses or can be taken all at once. Maltofer® drops should be taken during or immediately after a meal. Maltofer® drops can be mixed with fruit and vegetable juices or with bottle-feed. The slight discolouration of the mixture does not affect either the efficacy of the product or the taste of the drink to which it is added. To ensure accurate dosing of Maltofer® drops, the bottle needs to be held upside down and vertical. The drops should flow immediately. If this does not happen, tap the bottle gently until a drop forms. Do not shake the bottle.
Contraindications
Known hypersensitivity or intolerance to iron(III)-hydroxide polymaltose complex or any of the excipients
Iron overload (e.g. haemochromatosis, haemosiderosis)
Disturbances in iron utilisation (e.g. anaemia from lead-poisoning, sidero-achrestic anaemia, thalassaemia)
Anaemia not caused by iron deficiency (e.g. haemolytic anaemia or megaloblastic anaemia due to vitamin B12 deficiency).
